NSC746364, NSC746365, and NSC746366: The spectra of cytotoxicity and molecular correlates of response to telomerase activity

Hsu Shan Huang, Kuo Feng Huang, Chia Chung Lee, Chun Liang Chen, Cho L. Li, Jing J. Lin

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

NSC746364, NSC746365, and NSC746366 are structurally novel 2,7-diamidoanthraquinone derivatives compared with other clinically used anticancer agents and have exhibited a unique multilog differential pattern of activity in our earlier studies. To systematically evaluate their potential anticancer activity, three selected compounds were tested for their cytotoxicity in vitro against 60 human cancer lines in the National Cancer Institute's anticancer drug screen as well as for dose response curves and telomerase activity. Cell growth was analyzed by the MTT assay, with differences between dose-response curves analyzed nonparametrically. Telomerase activity was detected by a modified version of the PCR-based assay and telomere repeat amplification protocol assay. To elucidate the structure-activity relationships and in-vitro anticancer activity, we correlated their activity profile [GI50, total growth inhibition (TGI), and LC50] in the screening system and also their effects on telomerase activity, human telomerase reverse transcriptase expression, cell proliferations, and cytotoxicity. As a result we found that NSC746364, NSC746365, and NSC746366 have potent activity with 50% net growth inhibition conferred by 0.23-16.0μmol/l (2.08μmol/l mean); 0.78-15.9μmol/l (2.57μmol/l mean); 1.38-63.1μmol/l (3.89μmol/l mean), respectively. Sensitive cell lines exhibit TGI and 50% lethality to NSC746364, exhibited an LC50 with as little as 2.82μmol/l and TGI with as little as 0.95μmol/l; NSC746365, exhibited an LC50 with as little as 3.30μmol/l, and TGI with as little as 1.65μmol/l; NSC746366, exhibited an LC50 with as little as 8.80μmol/l; and TGI with as little as 4.06μmol/l, respectively. Results of the study extend the initial in-vitro observation reported in the data above and confirm the importance of anticancer activity and telomerase inhibition. The unique molecular characterization, cytotoxicity, and telomerase activity profiles warrant further investigation and indicate a potential novel mechanism of anticancer action involved.

Original languageEnglish
Pages (from-to)169-180
Number of pages12
JournalAnti-Cancer Drugs
Volume21
Issue number2
DOIs
Publication statusPublished - Feb 2010
Externally publishedYes

Fingerprint

Telomerase
Growth
National Cancer Institute (U.S.)
Telomere
Structure-Activity Relationship
Antineoplastic Agents
Cell Proliferation
Observation
Cell Line
Polymerase Chain Reaction
Pharmaceutical Preparations
In Vitro Techniques
Neoplasms

Keywords

  • Cytotoxicity
  • National Cancer Institute's anticancer drug screen
  • NSC746364
  • NSC746365
  • NSC746366
  • Telomerase activity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology (medical)
  • Pharmacology

Cite this

NSC746364, NSC746365, and NSC746366 : The spectra of cytotoxicity and molecular correlates of response to telomerase activity. / Huang, Hsu Shan; Huang, Kuo Feng; Lee, Chia Chung; Chen, Chun Liang; Li, Cho L.; Lin, Jing J.

In: Anti-Cancer Drugs, Vol. 21, No. 2, 02.2010, p. 169-180.

Research output: Contribution to journalArticle

Huang, Hsu Shan ; Huang, Kuo Feng ; Lee, Chia Chung ; Chen, Chun Liang ; Li, Cho L. ; Lin, Jing J. / NSC746364, NSC746365, and NSC746366 : The spectra of cytotoxicity and molecular correlates of response to telomerase activity. In: Anti-Cancer Drugs. 2010 ; Vol. 21, No. 2. pp. 169-180.
@article{d2860fa035b242949c8decdc1c5b0618,
title = "NSC746364, NSC746365, and NSC746366: The spectra of cytotoxicity and molecular correlates of response to telomerase activity",
abstract = "NSC746364, NSC746365, and NSC746366 are structurally novel 2,7-diamidoanthraquinone derivatives compared with other clinically used anticancer agents and have exhibited a unique multilog differential pattern of activity in our earlier studies. To systematically evaluate their potential anticancer activity, three selected compounds were tested for their cytotoxicity in vitro against 60 human cancer lines in the National Cancer Institute's anticancer drug screen as well as for dose response curves and telomerase activity. Cell growth was analyzed by the MTT assay, with differences between dose-response curves analyzed nonparametrically. Telomerase activity was detected by a modified version of the PCR-based assay and telomere repeat amplification protocol assay. To elucidate the structure-activity relationships and in-vitro anticancer activity, we correlated their activity profile [GI50, total growth inhibition (TGI), and LC50] in the screening system and also their effects on telomerase activity, human telomerase reverse transcriptase expression, cell proliferations, and cytotoxicity. As a result we found that NSC746364, NSC746365, and NSC746366 have potent activity with 50{\%} net growth inhibition conferred by 0.23-16.0μmol/l (2.08μmol/l mean); 0.78-15.9μmol/l (2.57μmol/l mean); 1.38-63.1μmol/l (3.89μmol/l mean), respectively. Sensitive cell lines exhibit TGI and 50{\%} lethality to NSC746364, exhibited an LC50 with as little as 2.82μmol/l and TGI with as little as 0.95μmol/l; NSC746365, exhibited an LC50 with as little as 3.30μmol/l, and TGI with as little as 1.65μmol/l; NSC746366, exhibited an LC50 with as little as 8.80μmol/l; and TGI with as little as 4.06μmol/l, respectively. Results of the study extend the initial in-vitro observation reported in the data above and confirm the importance of anticancer activity and telomerase inhibition. The unique molecular characterization, cytotoxicity, and telomerase activity profiles warrant further investigation and indicate a potential novel mechanism of anticancer action involved.",
keywords = "Cytotoxicity, National Cancer Institute's anticancer drug screen, NSC746364, NSC746365, NSC746366, Telomerase activity",
author = "Huang, {Hsu Shan} and Huang, {Kuo Feng} and Lee, {Chia Chung} and Chen, {Chun Liang} and Li, {Cho L.} and Lin, {Jing J.}",
year = "2010",
month = "2",
doi = "10.1097/CAD.0b013e3283324d0a",
language = "English",
volume = "21",
pages = "169--180",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - NSC746364, NSC746365, and NSC746366

T2 - The spectra of cytotoxicity and molecular correlates of response to telomerase activity

AU - Huang, Hsu Shan

AU - Huang, Kuo Feng

AU - Lee, Chia Chung

AU - Chen, Chun Liang

AU - Li, Cho L.

AU - Lin, Jing J.

PY - 2010/2

Y1 - 2010/2

N2 - NSC746364, NSC746365, and NSC746366 are structurally novel 2,7-diamidoanthraquinone derivatives compared with other clinically used anticancer agents and have exhibited a unique multilog differential pattern of activity in our earlier studies. To systematically evaluate their potential anticancer activity, three selected compounds were tested for their cytotoxicity in vitro against 60 human cancer lines in the National Cancer Institute's anticancer drug screen as well as for dose response curves and telomerase activity. Cell growth was analyzed by the MTT assay, with differences between dose-response curves analyzed nonparametrically. Telomerase activity was detected by a modified version of the PCR-based assay and telomere repeat amplification protocol assay. To elucidate the structure-activity relationships and in-vitro anticancer activity, we correlated their activity profile [GI50, total growth inhibition (TGI), and LC50] in the screening system and also their effects on telomerase activity, human telomerase reverse transcriptase expression, cell proliferations, and cytotoxicity. As a result we found that NSC746364, NSC746365, and NSC746366 have potent activity with 50% net growth inhibition conferred by 0.23-16.0μmol/l (2.08μmol/l mean); 0.78-15.9μmol/l (2.57μmol/l mean); 1.38-63.1μmol/l (3.89μmol/l mean), respectively. Sensitive cell lines exhibit TGI and 50% lethality to NSC746364, exhibited an LC50 with as little as 2.82μmol/l and TGI with as little as 0.95μmol/l; NSC746365, exhibited an LC50 with as little as 3.30μmol/l, and TGI with as little as 1.65μmol/l; NSC746366, exhibited an LC50 with as little as 8.80μmol/l; and TGI with as little as 4.06μmol/l, respectively. Results of the study extend the initial in-vitro observation reported in the data above and confirm the importance of anticancer activity and telomerase inhibition. The unique molecular characterization, cytotoxicity, and telomerase activity profiles warrant further investigation and indicate a potential novel mechanism of anticancer action involved.

AB - NSC746364, NSC746365, and NSC746366 are structurally novel 2,7-diamidoanthraquinone derivatives compared with other clinically used anticancer agents and have exhibited a unique multilog differential pattern of activity in our earlier studies. To systematically evaluate their potential anticancer activity, three selected compounds were tested for their cytotoxicity in vitro against 60 human cancer lines in the National Cancer Institute's anticancer drug screen as well as for dose response curves and telomerase activity. Cell growth was analyzed by the MTT assay, with differences between dose-response curves analyzed nonparametrically. Telomerase activity was detected by a modified version of the PCR-based assay and telomere repeat amplification protocol assay. To elucidate the structure-activity relationships and in-vitro anticancer activity, we correlated their activity profile [GI50, total growth inhibition (TGI), and LC50] in the screening system and also their effects on telomerase activity, human telomerase reverse transcriptase expression, cell proliferations, and cytotoxicity. As a result we found that NSC746364, NSC746365, and NSC746366 have potent activity with 50% net growth inhibition conferred by 0.23-16.0μmol/l (2.08μmol/l mean); 0.78-15.9μmol/l (2.57μmol/l mean); 1.38-63.1μmol/l (3.89μmol/l mean), respectively. Sensitive cell lines exhibit TGI and 50% lethality to NSC746364, exhibited an LC50 with as little as 2.82μmol/l and TGI with as little as 0.95μmol/l; NSC746365, exhibited an LC50 with as little as 3.30μmol/l, and TGI with as little as 1.65μmol/l; NSC746366, exhibited an LC50 with as little as 8.80μmol/l; and TGI with as little as 4.06μmol/l, respectively. Results of the study extend the initial in-vitro observation reported in the data above and confirm the importance of anticancer activity and telomerase inhibition. The unique molecular characterization, cytotoxicity, and telomerase activity profiles warrant further investigation and indicate a potential novel mechanism of anticancer action involved.

KW - Cytotoxicity

KW - National Cancer Institute's anticancer drug screen

KW - NSC746364

KW - NSC746365

KW - NSC746366

KW - Telomerase activity

UR - http://www.scopus.com/inward/record.url?scp=76149124850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76149124850&partnerID=8YFLogxK

U2 - 10.1097/CAD.0b013e3283324d0a

DO - 10.1097/CAD.0b013e3283324d0a

M3 - Article

C2 - 19884821

AN - SCOPUS:76149124850

VL - 21

SP - 169

EP - 180

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 2

ER -